Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Targeted therapies are revolutionizing cancer treatment.
• Trastuzumab is a pioneering monoclonal antibody targeting the HER2 protein.
• Its development exemplifies integrating novel agents with traditional cancer therapies.

Purpose of the Study:

• To evaluate the efficacy and safety of Trastuzumab in HER2-positive cancers.
• To assess Trastuzumab's role as a monotherapy and in combination regimens.
• To explore Trastuzumab's potential in various treatment settings, including adjuvant and neoadjuvant therapy.

Main Methods:

• Preclinical studies assessing antiproliferative effects and synergy with chemotherapy.
• Clinical trials evaluating Trastuzumab monotherapy and combination therapy in HER2-positive patients.
• Analysis of objective response rates, time to disease progression, and survival outcomes.

Main Results:

• Trastuzumab demonstrated marked antiproliferative effects and synergistic action with chemotherapy in preclinical models.
• Monotherapy with Trastuzumab showed activity, tolerability, and preserved quality of life in HER2-positive patients.
• Combination therapy with Trastuzumab significantly improved response rates, delayed progression, and increased survival in metastatic breast cancer.

Conclusions:

• Trastuzumab is an effective targeted therapy for HER2-positive cancers, particularly metastatic breast cancer.
• It offers significant clinical benefits when used as a single agent or in combination with chemotherapy.
• Ongoing research aims to optimize Trastuzumab's use in different treatment settings and patient populations.